Research use only. NeuroPD studies EEG-biomarker robustness across datasets. It does not diagnose Parkinson's disease and is not a medical device.
The cohorts

Two independent resting-state EEG datasets

Both are public (CC0), eyes-open resting-state recordings, harmonized to 31 shared 10–20 electrodes. They differ in hardware, sampling rate, country, and class balance — exactly the differences a transferable biomarker must survive.

datasetrolenPD / HCage (range)malefeatures
ds007526development133106 / 2765 (39–84)59%210
ds002778external validation3015 / 1563 (47–82)47%210

Counts are after quality control. The development cohort is imbalanced (~4:1 PD:HC) and its patients are older and more male than controls — a confound quantified on the Results page. The external cohort is age/sex-balanced, which is why the demographic shortcut fails to transfer.